Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

Blood

Volumn 127, Issue 6, 2016, Pages 681-695

  Van De Donk, Niels W C J ^a   Moreau, Philippe ^b   Plesner, Torben ^c   Palumbo, Antonio ^d   Gay, Francesca ^d   Laubach, Jacob P ^e   Malavasi, Fabio ^f   Avet Loiseau, Hervé ^g   Mateos, Maria Victoria ^h   Sonneveld, Pieter ⁱ   Lokhorst, Henk M ^a   Richardson, Paul G ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF TURIN   (Italy)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g L'Institut Universitaire Du Cancer de Toulouse Oncopole   (France)

^h CSIC   (Spain)

ⁱ ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; ISATUXIMAB; LENALIDOMIDE; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE F7; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN RECEPTOR; SLAMF7 PROTEIN, HUMAN;

BLOOD COMPATIBILITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ELECTROPHORESIS; FLOW CYTOMETRY; HUMAN; IMMUNOFIXATION ELECTROPHORESIS; INFUSION RELATED REACTION; LABORATORY TEST; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SERUM PROTEIN ELECTROPHORESIS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD38; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; RECEPTORS, IMMUNOLOGIC; TREATMENT OUTCOME;

EID: 84959423326     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-646810     Document Type: Review

References (100)

1. van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013;14(12):1569-1573.
2. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1): 149-157.
3. Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014; 199-203.
4. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42-54.
5. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199-213.
6. Raje N, Longo DL. Monoclonal Antibodies in Multiple Myeloma Come of Age. N Engl J Med. 2015;373(13):1264-1266.
7. Lonial S, Durie B, Palumbo A, San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives [published online ahead of print August 12, 2015]. Leukemia. doi:10.1038/leu.2015.223.
8. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5): 317-327.
9. Ferris RL, Jaffee EM, Ferrone S. Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390-4399.
10. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775-2784.
11. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4): 1329-1337.
12. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841-1849.
13. Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841-886.
14. Horenstein AL, Chillemi A, Zaccarello G, et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. OncoImmunology. 2013;2(9):e26246.
15. Malavasi F. Editorial: CD38 and retinoids: A step toward a cure. J Leukoc Biol. 2011;90(2): 217-219.
16. Quarona V, Ferri V, Chillemi A, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci. 2015;1335:10-22.
17. Vaisitti T, Aydin S, Rossi D, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010;24(5):958-969.
18. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: A decade later. Blood. 2011;118(13):3470-3478.
19. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]. Blood. 2014;124(21). Abstract 3474.
20. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD381 hematologic malignancies. Clin Cancer Res. 2014;20(17):4574-4583.
21. Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-321.
22. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2): 284-290.
23. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
24. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015; 29(10):2039-2049.
25. Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti- KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263-268.
26. Endell J, Boxhammer R, Wurzenberger C, Ness D, Steidl S. The activity of MOR202, a fully human anti-CD38 antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and in vivo [abstract]. Blood. 2012;120(21). Abstract 4018.
27. Tesar M. Fully human antibody MOR202 against CD38 for the treatment of multiple myeloma and other blood-borne malignancies [abstract]. J Clin Oncol. 2015;25(18S). Abstract 8106.
28. Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide [published online ahead of print September 4, 2015]. Leukemia. doi:10.1038/leu.2015.240.
29. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012; 120(3):552-559.
30. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
31. Lonial S, Usmani S, Singha UK, et al. Phase II study of daratumumab (DARA) monotherapy in patients with $3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) [abstract]. J Clin Oncol. 2015;33(suppl). Abstract LBA8512. 32. Martin TG, Strickland SA, Glenn M, Zheng W, .
32. Daskalakis N, Mikhael JR. SAR650984, a CD38 monoclonal antibody in patients with selected CD381 hematological malignancies: data from a dose-escalation phase I study [abstract]. Blood. 2013;122(21). Abstract 284.
33. Martin T, Hsu K, Strickland SA, Glenn M, Mikhael JR, Charpentier E. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma [abstract]. J Clin Oncol. 2014;32(5S). Abstract 8532.
34. Raab M, Chatterjee M, Goldschmidt H, et al. A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma [abstract]. Clin Lymphoma Myeloma Leuk. 2015;15(suppl 3):e80. Abstract BP-058.
35. Raab S, Goldschmidt HM, Agis H, et al. A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM) [abstract]. J Clin Oncol. 2015;33(suppl). Abstract 8574.
36. Raab S, Goldschmidt H, Agis H, et al. A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma [abstract]. Haematologica. 2015;100(suppl 1). Abstract S789.
37. Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38- targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12): 2802-2810.
38. van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
39. Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-a pathways. Cancer Immunol Immunother. 2015;64(1):61-73.
40. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocytemediated antibody-dependent cellular cytotoxicity of rituximab-treated CD201 tumor cells. Clin Cancer Res. 2008;14(14):4650-4657.
41. Jiang H, An G, Acharya C, et al. SAR650984 (SAR) directly promotes homotypic adhesionrelated multiple myeloma (MM) cell death and SAR-induced anti-MM activities are enhanced by pomalidomide, more potently than lenalidomide [abstract]. Blood. 2014;124(21). Abstract 2124.
42. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
43. Jakubowiak A, Offidani M, Pegourie B, et al. A randomized, open-label, phase 2 study of bortezomib and dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma [abstract]. Haematologica. 2015;100(suppl 1). Abstract S103.
44. Plesner T, Arkenau T, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 84.
45. Plesner T, Arkenau T, Gimsing P, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503) [abstract]. Blood. 2015;126(23). Abstract 507.
46. Chari A, Lonial S, Suvannasankha A, et al. Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract]. Blood. 2015;126(23). Abstract 508.
47. Martin TG, Baz R, Benson DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 83.
48. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012; 30(16):1953-1959.
49. Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 302.
50. Richardson P, Jagannath S, Moreau P. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 doseescalation study. Lancet Haematol. 2015;2(12): e516-e527.
51. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
52. Moreau P, Mateos MV, Blade J, et al. An openlabel, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 176.
53. van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616-2624.
54. Cai T, Wetzel M, Nicolazzi C, et al. Preclinical chracterization of SAR650984, a humanized anti-CD38 antibody for the treatment of multiple myeloma [abstract]. Clin Lymphoma Myeloma Leuk. 2013;13(suppl 1). Abstract P288.
55. Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960-1965.
56. Sondergeld P, van de Donk NW, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9): 599-609.
57. Nijhof IS, Axel A, Casneuf T, et al. Expression levels of CD38 and complement inhibitory proteins CD55 and CD59 predcit response to daratumumab in multipe myeloma [abstract]. Haematologica. 2015;100(suppl 1). Abstract S477.
58. Funaro A, Horenstein AL, Calosso L, et al. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int Immunol. 1996;8(11): 1643-1650.
59. Marra J, Du J, Hwang J, et al. KIR and HLA genotypes influence clinical outcome in multiple myeloma patients treated with SAR650984 (anti- CD38) in combination with lenalidomide and dexamethasone [abstract]. Blood. 2014;124(21). Abstract 2126.
60. Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl): 54S-62S.
61. Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol. 2002;71(3): 219-222.
62. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
63. Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981-992.
64. McCudden CR, Axel A, Slaets D, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody [abstract]. J Clin Oncol. 2015;33(suppl). Abstract 8590.
65. Jacobs JF, van der Molen RG, Keren DF. Relatively restricted migration of polyclonal IgG4 may mimic a monoclonal gammopathy in IgG4- related disease. Am J Clin Pathol. 2014;142(1): 76-81.
66. Jeppsson JO, Laurell CB, Franźen B. Agarose gel electrophoresis. Clin Chem. 1979;25(4): 629-638.
67. Axel A, McCudden CR, Xie H, Hall B, Sasser K. Development of clinical assay to mitigate daratumumab, an IgG1- monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma [abstract]. Cancer Res. 2014; 74(19 suppl). Abstract 2563.
68. Schmitz MF, Otten HG, Franssen LE, et al. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. Haematologica. 2014;99(12):1846-1853.
69. Dimopoulos M, Lonial S, Palumbo A, et al. Eloquent-2: A phase 3, randomized, open-label study of lenalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma [abstract]. Haematologica. 2015;100(suppl 1). Abstract S471.
70. Dimopoulos M, Lonial S, Casado L, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma [abstract]. Clin Lymphoma Myeloma Leuk. 2015;15(suppl 3). Abstract 330.
71. McCudden CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem. 2010;56(12):1897-1899.
72. Ruinemans-Koerts J, Verkroost C, Schmidt- Hieltjes Y, et al. Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins. Clin Chem Lab Med. 2014;52(11): e235-e237.
73. Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol. 2011;155(1):123-125.
74. Paiva B, Vidriales MB, Cerveŕo J, et al; GEM (Grupo Españ ol de MM)/PETHEMA (Programa para el Estudio de la Terap eutica en Hemopatias Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10): 4017-4023.
75. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
76. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-397.
77. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.
78. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059-3068.
79. Rawstron AC, Pavia B, Stetler-Stevenson M. Assessment of minimal residual disease in myeloma and the need for a consensus approach [published online ahead of print July 22, 2015]. Cytometry B Clin Cytom. doi:10.1002/cyto.b.21272.
80. Rawstron AC, Orfao A, Beksac M, et al; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438.
81. San-Miguel JF, Paiva B, Gutíerrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;10:e313.
82. Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma [published online ahead of print June 23, 2015]. Cytometry B Clin Cytom. doi:10.1002/cyto.b.21265.
83. Moulard M, Ozoux ML. How validated receptor occupancy flow cytometry assays can impact decisions and support drug development [published online ahead of print August 31, 2015]. Cytometry B Clin Cytom. doi:10.1002/cyto.b.21320.
84. Frigyesi I, Adolfsson J, Ali M, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014;123(9):1336-1340.
85. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015; 55(6 Pt 2):1555-1562.
86. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015; 55(6 Pt 2):1545-1554.
87. Zocchi E, Franco L, Guida L, et al. A single protein immunologically identified as CD38 displays NAD1 glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196(3):1459-1465.
88. Albeniz I, Demir O, Turker-Sener L, Yalçintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. Hematology. 2007; 12(5):409-414.
89. Jagannath S, Chanan-Khan A, Heffner LT, et al. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma [abstract]. Blood. 2011;118(21). Abstract 305.
90. Heffner LT, Jagannath S, Zimmerman TM, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity [abstract]. Blood. 2012;120(21). Abstract 4042.
91. Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib [abstract]. Blood. 2014;124(21). Abstract 4736.
92. Berdeja JG, Hernandez-Ilizaliturri F, Chanan- Khan A, et al. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM) [abstract]. Blood. 2012;120(21). Abstract 728.
93. Chanan-Khan A, Wolf JL, Garcia J, et al. Efficacy analysis from phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma: A preliminary efficacy analysis [abstract]. Blood. 2010;116(21). Abstract 1962.
94. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10): 3044-3051.
95. Mahadevan D, Lanasa MC, Whelden M, et al. First-in-human phase I dose escalation study of a humanized anti-CD200 antibody (samalizumab) in patients with advanced stage B cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) [abstract]. Blood. 2010; 116(21). Abstract 2465.
96. Siegel D, Moreau P, Avigan D, et al. A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol 2014;32(5 suppl). Abstract TPS3117.
97. Lesokhin A, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract]. Blood. 2014;124(21). Abstract 291.
98. Ghobrial IM, Perez R, Baz R, et al. Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 3483.
99. Raje N, Faber EA Jr, Richardson PG, et al. Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously treated multiple myeloma [abstract]. Blood. 2012;120(21). Abstract 447.
100. Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163(4):478-486.